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Klebsiella bacteria evade humoral immunity by altering their polysaccharide capsular antigens. In this issue
of Immunity, Chen et al. (2011) propose a new vaccination strategy, demonstrating that Th17 memory cells
can provide cross-protection against multiple serotypes of Klebsiella pneumoniae.Th17 cells have received much attention
for their roles in chronic inflammatory
conditions such as psoriasis and Crohn’s
disease. However, this was clearly not
the reason this response evolved. Th17
cells are thought to be important for
defense against extracellular bacteria,
including Klebsiella, Streptococcus, and
Staphlyoccocus, as well as fungal patho-
gens such as Candida. The putative
Th17 cell cytokine, IL-17, promotes clear-
ance of these agents through induction
of neutrophil-recruiting chemokines and
the cytokine G-CSF. IL-22, another Th17
cell-produced cytokine, synergizes with
IL-17 in induction of chemokines as well
as upregulating expression of antimicro-
bial peptides. However, both IL-17 and
IL-22 are also produced by innate immune
cells, including gd T cells, lymphoid
tissue-inducer (LTi)-like cells, and NKT
cells. Therefore, the role of bona fide
Th17 cells versus these other ‘‘type-17’’
cells in host defense is not always clear.
One of the main differences between
adaptive and innate immune responses
is that, after activation, B and T cells are
able to form long-lived memory cells that
respond rapidly to future invasion by the
same pathogen. It is the ability of these
memory cells to clear future infections
before the host becomes ill that forms
the basis of vaccination. By immunizing
mice intranasally with heat-killed Klebsi-
ella pneumoniae (i.e., vaccinating them),
Chen et al. (2011) in this issue of Immunity
found that Th17 cells expanded in
draining lymph nodes (LNs) and lungs.
Vaccinated mice were subsequently pro-
tected from challenge with a lethal dose
of the same serotype of live Klebsiella.
However, protection was mediated by
antibody and surprisingly independent of
IL-17, IL-22, or neutrophils. The authors
therefore looked for a function for the
Th17 cells activated by vaccination and854 Immunity 35, December 23, 2011 ª2011found two instances in which Th17 cells
became crucial for protecting the host.
First, in the absence of B cells and
antibody, vaccinated mice were still pro-
tected against Klebsiella infection; anti-
body-independent protection required
IL-17 and could be transferred to RAG-
deficient hosts by IL-17+ CD4+ T cells.
Second, unlike antibody, Th17 cells were
able to respond to and to protect against
other serotypes ofKlebsiella pneumoniae,
including the multidrug resistant New
Delhi metallolactamase strain (Figure 1).
This clade-specific protection was based
on T cell recognition of conserved outer
membrane proteins, and thus it is pro-
posed that an effective vaccine strategy
for highly pathogenic strains of Klebsiella
could involve use of these proteins in
conjunction with a Th17 cell-favoring
adjuvant. Current adjuvants licensed for
use in humans were developed with the
humoral response in mind, so in addition
to further investigating the best subunits
to generate the effective Th17 cell re-
sponse, attention must be paid to the
adjuvant in which they are delivered.
In addition to the implications for
vaccination, this study provides some
insight into the development of memory
Th17 cells. Currently, very limited data
on memory Th17 cell responses exist. In
humans, memory-phenotype cells pro-
duce IL-17 in response to various patho-
gens, but it is difficult to distinguish
effector cells from true memory cells in
human subjects. In a murine vaccination
model for Mycobacterium tuberculosis,
Th17 cells enabled the Th1 effector
memory cell response by inducing Th1
cell-recruiting chemokines in the lung
(Khader et al., 2007). IL-17 was also
required for vaccine-induced protection
from infection with three fungal patho-
gens that target the lung (Wu¨thrich et al.,
2011). In contrast, Pepper et al. (2010)Elsevier Inc.compared two routes of infection with
Listeria monocytogenes and found that
systemic infection induced a Th1 cell
response that sustained memory IFN-
g-producing cells for over 100 days,
whereas intranasal infection induced a
transient Th17 cell response that resulted
in few IL-17+ effector memory cells. The
conclusion was that Th17 cell responses
are transient compared to robust Th1
cell responses, although the ability of
these cells to protect during rechallenge
with Listeria was not tested. In the study
from Chen et al. (2011), the generation of
Th17 memory cells is demonstrated by
their ability to protect the host against
rechallenge with Klebsiella, in an IL-17-
dependent manner. This protection was
very rapid, within 24 hr of rechallenge,
suggesting an effector memory response
rather than expansion of a central pop-
ulation that was not producing IL-17.
How can these differences be explained?
Both studies challenge via the intranasal
route, with transient stimuli. Pepper
et al. used tetramers to identify antigen-
specific Th17 cells in draining LNs over
more than 100 days, whereas Chen et al.
followed total IL-17-producing cells in
LNs and the lung for only 28 days and
relied on infectious challenge to test
the functional memory response. Th17
cells are thought to be most important
against extracellular pathogens, and this
paradigm is supported by the induction
of Th17 memory cells by Klebsiella
pneumoniae. In contrast, Listeria mono-
cytogenes is an intracellular pathogen
that typically induces a Th1 cell and
CD8+ T cell response against systemic
infection after oral exposure, but does
not usually infect via the intranasal route.
It is very interesting that the route of infec-
tion made such a large difference in T cell
cytokines induced by the same organism,
suggesting that the local cytokine milieu
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Figure 1. Th17 Memory cells in Klebsiella Infection
Vaccination with Klebsiella pneumonia serotype K2 induces antibody and Th17 cell responses resulting in
immune memory. Hosts are protected from reinfection with K2 serotype by antibody, and Th17 cells are
not required. When infected with another serotype (K16 or K1), antibody does not recognize Klebsiella, but
Th17 memory cells are activated to protect by producing IL-17 and IL-22 to activate antimicrobial defense
mechanisms such as neutrophil recruitment. Similarly, when antibody is absent, memory Th17 cells
protect against serotype K2.
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addition to receptors triggered by the
microbe. It would also be interesting to
compare the cytokines and costimulatory
molecules induced in response to these
two pathogens.
Another new report in this issue of
Immunity from Muranski et al. (2011)
again finds that Th17 cells persist in vivo
over a 2 month study period. Using trans-
genic T cells that recognize TRP-1 antigen
from melanocytes, Muranski et al. show
that in vitro-generated Th17 cells are
more effective than Th1 cells for tumor
eradication and driving autoimmune viti-
ligo. Despite bearing markers of terminal
differentiation, Th17 cells maintain a
gene signature reminiscent of stem cells,
and their in vivo function requires not
only IL-17 but also induction of IFN-g,
suggesting that the stem cell-like proper-
ties of Th17 cells may contribute not only
to longevity but also to increased flexi-
bility in the phenotype of these cells. In
recent years, there has been considerable
interest in the field in the plasticity of Th17
cells. Although it has become apparent
that most T cell subsets demonstrate
flexibility in their expression of cytokines
and even transcription factors, Th17 cells
seem particularly prone to altering their
phenotype. In human chronic autoim-mune conditions, and the corresponding
mouse models, Th17 cells are often
found to coproduce IFN-g, the putative
Th1 cell cytokine. Furthermore, several
studies have shown that Th17 cells readily
convert to a Th1 cell phenotype in vitro
and in vivo, particularly in models of
autoimmunity (Murphy and Stockinger,
2010), again suggesting that Th17 cell
responses would be transient in nature.
Most recently, Hirota et al. (2011) utilized
fate-tracking of IL-17+ cells in experi-
mental autoimmune encephalomyelitis
and found that most of the effector Th1
cells in the inflamed brain were derived
from precursors that originally produced
IL-17. Similarly, Muranski et al. (2011)
find that melanocyte-specific Th17 cells
upregulate T-bet and IFN-g while down-
regulating IL-17, yet maintain enhanced
antitumor and autoimmune function
compared to bona fide Th1 cells. By com-
paring ‘‘ex-Th17’’ cells with Th1 cells, they
show that the gene signature remains
quite distinct in these populations, so
the fate of these converting Th17 cells
appears to be less straightforward than
a simple switch from Th17 to Th1.
In contrast, during dermal infection
with Candida, Th17 cells were abundant
in the skin but produced little IFN-g
(Hirota et al., 2011). Similarly, Chen et al.Immunity 35, Dobserved that intranasal vaccination
with Klebsiella pneumoniae leads to an
IL-17-dominated response in the draining
LN, spleen, and lung; IL-17+ cells also
proliferated in response to all Klebsiella
serotypes tested. In contrast, they ob-
served little change in the IFN-g-pro-
ducing population. In the memory recall
response, protection against heterolo-
gous serotypes of Klebsiella was depen-
dent on IL-17, but not IFN-g, confirming
that protection was mediated by bona
fide Th17 cells. One difference between
these types of infections and autoimmu-
nity is that bacteria are rapidly cleared
from the system, whereas autoimmunity
leads to chronic stimulation of responding
T cells. In support of this, acute infection
with Group A Streptococcus pyogenes
only gave IL-17 producers, but repeated
(and therefore chronic) infection resulted
in mixed Th17 and Th1 phenotype cells
(Dileepan et al., 2011). So it seems that
the duration of stimulation of Th17 cells
may influence whether they maintain
their Th17 cell phenotype or begin to
adopt Th1 cell characteristics. It would
be interesting to compare Th17 memory
cell responses in the setting of chronic
autoimmune disease, in which the more
mixed Th17 and Th1 cell phenotype
seems more common.
The factors required for functional acti-
vation of Th17 memory cells are not yet
fully elucidated. Chen et al. report that
in vitro IL-17 recall was not dependent
on IL-1 or IL-23, but was partially depen-
dent on MHC class II. Previous data on
the differentiation of Th17 cells caution
that in vitro results do not always corre-
late with in vivo findings, particularly for
IL-23 (McGeachy et al., 2009). These
questions become particularly important
in the context of therapies targeting
Th17 cell-mediated inflammatory dis-
ease, in which memory responses for
both self and infectious agents may be
impacted. For better vaccine design, the
conditions that favor the entry of Th17
cells into the memory pool require further
investigation: studies so far suggest the
type of pathogen appears to have more
influence over memory formation than
route of immunization, suggesting that
TLR-driven cytokines and/or costimula-
tory molecules may be important.
In conclusion, there is now clear
evidence that Th17 memory cells can
be generated, although further work isecember 23, 2011 ª2011 Elsevier Inc. 855
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Previewsrequired to fully understand this process.
By generating memory cells to fight path-
ogens that evade antibody responses,
Chen et al. nicely demonstrate that the
potent inflammatory function of the Th17
cell subset can be harnessed for good,
and point the way toward a new strategy
in vaccine development.
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